Correction to “Combined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4-mediated cell death in TP53-deficient ALL”

IF 11.3 2区医学 Q1 HEMATOLOGY

HemaSphere Pub Date : 2026-10-05 DOI:10.1002/hem3.70502

引用次数: 0

Abstract

Grünewald KJT, Kes MMG, Stoll GR, et al. Combined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4-mediated cell death in TP53-deficient ALL. HemaSphere. 2026;10(7):e70439. doi:10.1002/hem3.70439

In Figure 5, the abbreviation ATR was incorrectly defined as “Activating Transcription Factor 4” in the caption. The correct definition is “Ataxia Telangiectasia and Rad3-related (ATR) protein.”

We apologize for this error. The article has been corrected.

查看原文本刊更多论文

更正“联合抑制新生嘧啶合成和ATR促进tp53缺陷ALL中atf4介导的细胞死亡”。

[这更正了文章DOI: 10.1002/hem3.70439.]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

HemaSphere Medicine-Hematology

CiteScore

6.10

自引率

4.50%

发文量

2776

审稿时长

7 weeks

期刊介绍： HemaSphere, as a publication, is dedicated to disseminating the outcomes of profoundly pertinent basic, translational, and clinical research endeavors within the field of hematology. The journal actively seeks robust studies that unveil novel discoveries with significant ramifications for hematology. In addition to original research, HemaSphere features review articles and guideline articles that furnish lucid synopses and discussions of emerging developments, along with recommendations for patient care. Positioned as the foremost resource in hematology, HemaSphere augments its offerings with specialized sections like HemaTopics and HemaPolicy. These segments engender insightful dialogues covering a spectrum of hematology-related topics, including digestible summaries of pivotal articles, updates on new therapies, deliberations on European policy matters, and other noteworthy news items within the field. Steering the course of HemaSphere are Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison, alongside the guidance of an esteemed Editorial Board comprising international luminaries in both research and clinical realms, each representing diverse areas of hematologic expertise.